Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches
- PMID: 27175979
- DOI: 10.1080/17476348.2016.1177460
Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches
Abstract
Pseudomonas aeruginosa is a remarkably versatile environmental bacterium with an extraordinary capacity to infect the cystic fibrosis (CF) lung. Infection with P. aeruginosa occurs early, and although eradication can be achieved following early detection, chronic infection occurs in over 60% of adults with CF. Chronic infection is associated with accelerated disease progression and increased mortality. Extensive research has revealed complex mechanisms by which P. aeruginosa adapts to and persists within the CF airway. Yet knowledge gaps remain, and prevention and treatment strategies are limited by the lack of sensitive detection methods and by a narrow armoury of antibiotics. Further developments in this field are urgently needed in order to improve morbidity and mortality in people with CF. Here, we summarize current knowledge of pathophysiological mechanisms underlying P. aeruginosa infection in CF. Established treatments are discussed, and an overview is offered of novel detection methods and therapeutic strategies in development.
Keywords: Pseudomonas aeruginosa; airway; antibiotic; biofilm; cystic fibrosis; persistence; sputum.
Similar articles
-
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.Cochrane Database Syst Rev. 2014 Nov 10;(11):CD004197. doi: 10.1002/14651858.CD004197.pub4. Cochrane Database Syst Rev. 2014. PMID: 25383937 Updated. Review.
-
Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.Int J Med Microbiol. 2018 Dec;308(8):1053-1064. doi: 10.1016/j.ijmm.2018.10.003. Epub 2018 Oct 11. Int J Med Microbiol. 2018. PMID: 30377031
-
Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.Health Technol Assess. 2021 Nov;25(65):1-128. doi: 10.3310/hta25650. Health Technol Assess. 2021. PMID: 34806975 Clinical Trial.
-
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004197. doi: 10.1002/14651858.CD004197.pub3. Cochrane Database Syst Rev. 2009. PMID: 19821321 Updated. Review.
-
Eradication of early Pseudomonas infection in cystic fibrosis.Chron Respir Dis. 2009;6(2):99-107. doi: 10.1177/1479972309104661. Chron Respir Dis. 2009. PMID: 19411571 Review.
Cited by
-
Quantification of Mixed-Linkage β-Glucan (MLG) in Bacteria.Methods Mol Biol. 2024;2751:133-143. doi: 10.1007/978-1-0716-3617-6_9. Methods Mol Biol. 2024. PMID: 38265714
-
Burkholderia cepacia complex in cystic fibrosis: critical gaps in diagnosis and therapy.Ann Med. 2024 Dec;56(1):2307503. doi: 10.1080/07853890.2024.2307503. Epub 2024 Jan 23. Ann Med. 2024. PMID: 38261606 Free PMC article. Review.
-
Phylogenomics studies and molecular markers reliably demarcate genus Pseudomonas sensu stricto and twelve other Pseudomonadaceae species clades representing novel and emended genera.Front Microbiol. 2024 Jan 5;14:1273665. doi: 10.3389/fmicb.2023.1273665. eCollection 2023. Front Microbiol. 2024. PMID: 38249459 Free PMC article.
-
The dual GGDEF/EAL domain enzyme PA0285 is a Pseudomonas species housekeeping phosphodiesterase regulating early attachment and biofilm architecture.J Biol Chem. 2024 Feb;300(2):105659. doi: 10.1016/j.jbc.2024.105659. Epub 2024 Jan 16. J Biol Chem. 2024. PMID: 38237678 Free PMC article.
-
A systematic review of the clinical impact of small colony variants in patients with cystic fibrosis.BMC Pulm Med. 2023 Sep 1;23(1):323. doi: 10.1186/s12890-023-02611-4. BMC Pulm Med. 2023. PMID: 37658311 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
